share_log

Otonomy (NASDAQ:OTIC) Earns Hold Rating From Analysts at StockNews.com

Otonomy (NASDAQ:OTIC) Earns Hold Rating From Analysts at StockNews.com

Otonomy（纳斯达克股票代码：OTIC）获得StockNews.com分析师的持有评级
kopsource ·  2022/12/27 14:21

StockNews.com started coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report sent to investors on Saturday morning. The firm issued a hold rating on the biopharmaceutical company's stock.

StockNews.com 开始报道的股票 Otonomy（纳斯达克股票代码：OTIC — 获取评级） 在周六上午发给投资者的研究报告中。该公司对这家生物制药公司的股票发布了持有评级。

Separately, Piper Sandler lowered shares of Otonomy from an overweight rating to a neutral rating and dropped their price target for the company from $3.00 to $0.50 in a research note on Thursday, October 13th.

另外，派珀·桑德勒在10月13日星期四的一份研究报告中将Otonomy的股票评级从增持评级下调至中性评级，并将该公司的目标股价从3.00美元下调至0.50美元。

Get
获取
Otonomy
自治学
alerts:
警报：

Otonomy Price Performance

Otonomy 价格表现

Shares of Otonomy stock opened at $0.07 on Friday. The firm has a market capitalization of $4.23 million, a P/E ratio of -0.10 and a beta of 1.31. Otonomy has a 52 week low of $0.06 and a 52 week high of $2.59. The firm's 50 day moving average is $0.11 and its two-hundred day moving average is $0.68.

周五，Otonomy股票开盘价为0.07美元。该公司的市值为423万美元，市盈率为-0.10，beta值为1.31。Otonomy创下52周低点0.06美元，52周高点2.59美元。该公司的50天移动平均线为0.11美元，其两百天移动平均线为0.68美元。

Hedge Funds Weigh In On Otonomy

对冲基金权衡自主权

Hedge funds have recently added to or reduced their stakes in the stock. Requisite Capital Management LLC acquired a new stake in shares of Otonomy in the third quarter valued at approximately $44,000. Two Sigma Investments LP boosted its holdings in shares of Otonomy by 129.2% in the third quarter. Two Sigma Investments LP now owns 142,183 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 80,153 shares during the period. Lynx1 Capital Management LP boosted its holdings in shares of Otonomy by 7,609.6% in the third quarter. Lynx1 Capital Management LP now owns 2,312,880 shares of the biopharmaceutical company's stock valued at $682,000 after acquiring an additional 2,282,880 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Otonomy in the third quarter valued at approximately $1,621,000. Finally, State Street Corp boosted its holdings in shares of Otonomy by 5.1% in the first quarter. State Street Corp now owns 182,239 shares of the biopharmaceutical company's stock valued at $437,000 after acquiring an additional 8,839 shares during the period. 41.23% of the stock is currently owned by hedge funds and other institutional investors.
对冲基金最近增加了或减少了在该股中的股份。Requiend Capital Management LLC在第三季度收购了Otonomy股票的新股份，价值约为44,000美元。Two Sigma Investments LP在第三季度将其持有的Otonomy股票增加了129.2％。Two Sigma Investments LP在此期间又收购了80,153股股票后，现在拥有这家生物制药公司142,183股股票，价值42,000美元。Lynx1 Capital Management LP在第三季度将其持有的Otonomy股票增加了7,609.6％。在此期间又收购了2,282,880股股票后，Lynx1 Capital Management LP现在拥有这家生物制药公司的2312,880股股票，价值68.2万美元。Point72 Asset Management L.P. 在第三季度收购了Otonomy股票的新股份，价值约16.1万美元。最后，State Street Corp在第一季度将其持有的Otonomy股票增加了5.1％。State Street Corp在此期间又收购了8,839股股票后，现在拥有这家生物制药公司182,239股股票，价值43.7万美元。该股票的41.23％目前由对冲基金和其他机构投资者持有。

Otonomy Company Profile

Otonomy 公司简介

(Get Rating)

（获取评分）

Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.

Otonomy, Inc是一家生物制药公司，在美国开发神经病学疗法。该公司提供 OTO-313，一种持续暴露的N-甲基-D-天冬氨酸受体拮抗剂加环素配方，目前正在进行治疗耳鸣的II期临床试验；以及 OTO-413，一种大脑源性神经营养因子的持续暴露配方，正在进行用于修复耳蜗突触病和治疗噪音中言语听力障碍的IIa期临床试验。

See Also

另见

  • Get a free copy of the StockNews.com research report on Otonomy (OTIC)
  • Three Healthcare Penny Stocks to Watch In The New Year
  • Southwest Airlines Stock, There is a Lot to Love
  • MarketBeat: Week in Review 12/19 – 12/23
  • These Steelmakers Deserve A Place On Your 2023 Watch List
  • Inflation Cools, Where Does The S&P 500 Go Now
  • 免费获取 StockNews.com 关于自主学的研究报告（OTIC）的副本
  • 新年值得关注的三只医疗保健细价股
  • 西南航空股票，有很多值得爱的地方
  • MarketBeat：本周回顾 12 月 19 日 — 12 月 23 日
  • 这些钢铁制造商值得在你的 2023 年观察名单上占有一席之地
  • 通货膨胀降温，标准普尔500指数现在走向何方

Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Otonomy Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Otonomy及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发